BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
bioAffinity Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.51−0.22 (-5.90%)
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$40.59 (−92.04%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
bioAffinity Technologies, Inc. saw revenue fall 23.2% to $5.90M over the twelve months to Jun 30, 2026. Free cash flow was -$11.56M.
Revenue
$5.90M
-23.2% vs. a year earlier
Operating income
-$12.38M
TTM Q2 2026
Free cash flow
-$11.56M
TTM Q2 2026
EPS, diluted
-$8.66
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $18.35M
- P/E ratio
- –
- Price to sales
- 3.11
- Price to book
- 4.87
- Dividend yield
- –
- Free cash flow yield
- -63.01%
Fundamentals
- Revenue
- $5.90M
- Net income
- -$15.19M
- EPS, diluted
- -$8.66
- Free cash flow
- -$11.56M
- Book value per share
- $0.72
- Diluted shares
- 5M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$5.90M-23.2% YoY
Gross profit
–
Operating income
-$12.38M
Net income
-$15.19M
EPS, diluted
–
Free cash flow
-$11.56M
Reported periodTrailing twelve months